Latest News

Synthace bags US$35m for R&D cloud platform

The future of research? © Schäferle / Pixabay


by um

London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.

Synthace has developed an R&D platform which can enable scientists to automate experiments as well as sharing their results world-wide. This cloud platform promises to simplify and speed up development as well as improve reproducibility. “Synthace’s R&D cloud platform is helping life scientists completely change the way they develop new cures and therapeutics to solve humanity’s most pressing problems,” said CEO Guy Levy-Yurista. Their platform, Synthase believes, will lower the barriers to medical development by keeping up with accelerating innovation and reducing development costs.

The US$35m raised will go towards the company’s growth strategy. “To maximise impact, we need to expand access and reach to customers across the globe – at scale,” added Levy-Yurista.

Among the investors were Horizons Ventures and Sofinnova Partners.

EC signs prepurchase agreement with Valneva

It’s the 8th contract of the European Commission with a COVID-19 vaccine producer. Under the now signed agreement, Austrian-French (Lyon/Vienna)...

Curevac withdraws MAA of CVnCoV

CureVac announced that it will focus on a second-generation mRNA vaccine candidate in collaboration with the British pharma major GlaxoSmithKline....

Owlstone: US$59m for breath biopsy development

Cambridge-based breath biopsy specialist Owlstone Medical has closed its Series D financing round with US$59m, exceeding its initial target of...

EU ends litigation with AstraZeneca

The Commission announced that they have reached an agreement with the British drug maker to secure the delivery of the remaining 200 COVID-19 vaccine...

EIF supports translational med with €25m

On Fridey,  the European Investment Bank announced the first Horizon Europe-backed seed investment of its the European Investment Fund (EIF)...

EU orders up Valneva’s inactivated Covid-19 vaccine

The European Commission has approved an agreement with Valneva under which the French vaccine maker would supply up to 60 million doses of VLA2001,...

Bayer: Peptide deal with Gubra

The partnership utilises Gubra’s machine learning-based peptide drug discovery platform for fast screening and identification of potent therapeutic...